AIM: To determine the suitability of porous silicon photonic crystals for intraocular drug-delivery. METHODS: A rugate structure was electrochemically etched into a highly doped p-type silicon substrate to create a porous silicon film that was subsequently removed and ultrasonically fractured into particles. To stabilise the particles in aqueous media, the silicon particles were modified by surface alkylation (using thermal hydrosilylation) or by thermal oxidation. Unmodified particles, hydrosilylated particles and oxidised particles were injected into rabbit vitreous. The stability and toxicity of each type of particle were studied by indirect ophthalmoscopy, biomicroscopy, tonometry, electroretinography (ERG) and histology. RESULTS: No toxicity was observed with any type of the particles during a period of >4 months. Surface alkylation led to dramatically increased intravitreal stability and slow degradation. The estimated vitreous half-life increased from 1 week (fresh particles) to 5 weeks (oxidised particles) and to 16 weeks (hydrosilylated particles). CONCLUSION: The porous silicon photonic crystals showed good biocompatibility and may be used as an intraocular drug-delivery system. The intravitreal injectable porous silicon photonic crystals may be engineered to host a variety of therapeutics and achieve controlled drug release over long periods of time to treat chronic vitreoretinal diseases.
AIM: To determine the suitability of porous silicon photonic crystals for intraocular drug-delivery. METHODS: A rugate structure was electrochemically etched into a highly doped p-type silicon substrate to create a porous silicon film that was subsequently removed and ultrasonically fractured into particles. To stabilise the particles in aqueous media, the silicon particles were modified by surface alkylation (using thermal hydrosilylation) or by thermal oxidation. Unmodified particles, hydrosilylated particles and oxidised particles were injected into rabbit vitreous. The stability and toxicity of each type of particle were studied by indirect ophthalmoscopy, biomicroscopy, tonometry, electroretinography (ERG) and histology. RESULTS: No toxicity was observed with any type of the particles during a period of >4 months. Surface alkylation led to dramatically increased intravitreal stability and slow degradation. The estimated vitreous half-life increased from 1 week (fresh particles) to 5 weeks (oxidised particles) and to 16 weeks (hydrosilylated particles). CONCLUSION: The porous silicon photonic crystals showed good biocompatibility and may be used as an intraocular drug-delivery system. The intravitreal injectable porous silicon photonic crystals may be engineered to host a variety of therapeutics and achieve controlled drug release over long periods of time to treat chronic vitreoretinal diseases.
Authors: Frédérique Cunin; Thomas A Schmedake; Jamie R Link; Yang Yang Li; Jennifer Koh; Sangeeta N Bhatia; Michael J Sailor Journal: Nat Mater Date: 2002-09 Impact factor: 43.841
Authors: John C Hwang; Gaetano R Barile; William M Schiff; Michael D Ober; R Theodore Smith; Lucian V Del Priore; Michael R Turano; Stanley Chang Journal: Retina Date: 2006 Jul-Aug Impact factor: 4.256
Authors: Lingyun Cheng; Karl Y Hostetler; Jeffery Lee; Hyoung Jun Koh; James R Beadle; Kenichiro Bessho; Mitsuko Toyoguchi; Kathy Aldern; Jean-Marc Bovet; William R Freeman Journal: Invest Ophthalmol Vis Sci Date: 2004-11 Impact factor: 4.799
Authors: O Weijtens; R C Schoemaker; A F Cohen; F P Romijn; E G Lentjes; J van Rooij; J C van Meurs Journal: Am J Ophthalmol Date: 1998-05 Impact factor: 5.258
Authors: D F Martin; F L Ferris; D J Parks; R C Walton; S D Mellow; D Gibbs; N A Remaley; P Ashton; M D Davis; C C Chan; R B Nussenblatt Journal: Arch Ophthalmol Date: 1997-11
Authors: Jennifer S Andrew; Emily J Anglin; Elizabeth C Wu; Michelle Y Chen; Lingyun Cheng; William R Freeman; Michael J Sailor Journal: Adv Funct Mater Date: 2010-09-08 Impact factor: 18.808
Authors: Jennifer S Park; Joseph M Kinsella; Danielle D Jandial; Stephen B Howell; Michael J Sailor Journal: Small Date: 2011-06-01 Impact factor: 13.281
Authors: Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor Journal: Biomaterials Date: 2010-11-30 Impact factor: 12.479
Authors: Jay Chhablani; Alejandra Nieto; Huiyuan Hou; Elizabeth C Wu; William R Freeman; Michael J Sailor; Lingyun Cheng Journal: Invest Ophthalmol Vis Sci Date: 2013-02-01 Impact factor: 4.799
Authors: Kathrin I Hartmann; Alejandra Nieto; Elizabeth C Wu; William R Freeman; Jae Suk Kim; Jay Chhablani; Michael J Sailor; Lingyun Cheng Journal: J Ocul Pharmacol Ther Date: 2013-02-28 Impact factor: 2.671